David Lebovitz
Stock Analyst at Citigroup
(3.22)
# 961
Out of 4,884 analysts
95
Total ratings
65.62%
Success rate
7.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $57.50 | +35.65% | 4 | May 2, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $331.91 | +5.75% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $298.87 | +56.92% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $29.80 | +148.32% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $50.30 | -24.45% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $49.07 | -65.36% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $128.35 | -28.32% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $65.77 | -17.90% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $43.00 | -18.60% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.46 | +1,064.38% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $0.77 | +1,336.03% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $174.18 | +14.25% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $4.39 | +10,833.94% | 2 | Nov 3, 2020 |
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $57.50
Upside: +35.65%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $331.91
Upside: +5.75%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $298.87
Upside: +56.92%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $29.80
Upside: +148.32%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $50.30
Upside: -24.45%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $49.07
Upside: -65.36%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $128.35
Upside: -28.32%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $65.77
Upside: -17.90%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $43.00
Upside: -18.60%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.46
Upside: +1,064.38%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.77
Upside: +1,336.03%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $174.18
Upside: +14.25%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $4.39
Upside: +10,833.94%